Synthesis of novel discodermolide analogues with modified hydrogen-bonding donor/acceptor sites

Tetrahedron Letters

Volumn 44, Issue 49, 2003, Pages 8877-8882

  Paterson, Ian ^a   Delgado, Oscar ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DISCODERMOLIDE; HYDROGEN; TUBULIN;

ALDOL REACTION; ARTICLE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; MICROTUBULE; OXYGENATION; PROTEIN BINDING;

EID: 0242266535     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2003.09.172     Document Type: Article

References (35)

1. For recent reviews, see: (a) Paterson, I.; Florence, G. J. Eur. J. Org. Chem. 2003, 2193; (b) Kalesse, M. ChemBioChem 2000, 1, 171.
2. For recent reviews, see: (a) Paterson, I.; Florence, G. J. Eur. J. Org. Chem. 2003, 2193; (b) Kalesse, M. ChemBioChem 2000, 1, 171.
3. Isolation and structure determination: Gunasekera, S. P.; Gunasekera, M. ; Longley, R. E.; Schulte, G. K. J. Org. Chem. 1990, 55, 4912. Additions and corrections: J. Org. Chem. 1991, 56, 1346.
4. Isolation and structure determination: Gunasekera, S. P.; Gunasekera, M. ; Longley, R. E.; Schulte, G. K. J. Org. Chem. 1990, 55, 4912. Additions and corrections: J. Org. Chem. 1991, 56, 1346.
5. For biological studies, see: (a) ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243; (b) Schreiber, S. L.; Chen, J.; Hung, D. T. Chem. Biol. 1996, 3, 287; (c) Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1997, 52, 613; (d) Balachandran, R.; ter Haar, E.; Welsh, M. J.; Grant, S. G.; Day, B. W. Anti-Cancer Drugs 1998, 9, 67; (e) Martello, M. A.; McDaid, H. M.; Regl, D. L.; Yang, C. H.; Meng, D.; Pettus, T. R. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., III; Horwitz, S. B. Clin. Cancer Res. 2000, 6, 1978; (f) Kar, S.; Florence, G. J.; Paterson, I.; Amos, L. A. FEBS Letters 2003, 539, 34.
6. For biological studies, see: (a) ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243; (b) Schreiber, S. L.; Chen, J.; Hung, D. T. Chem. Biol. 1996, 3, 287; (c) Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1997, 52, 613; (d) Balachandran, R.; ter Haar, E.; Welsh, M. J.; Grant, S. G.; Day, B. W. Anti-Cancer Drugs 1998, 9, 67; (e) Martello, M. A.; McDaid, H. M.; Regl, D. L.; Yang, C. H.; Meng, D.; Pettus, T. R. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., III; Horwitz, S. B. Clin. Cancer Res. 2000, 6, 1978; (f) Kar, S.; Florence, G. J.; Paterson, I.; Amos, L. A. FEBS Letters 2003, 539, 34.
7. For biological studies, see: (a) ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243; (b) Schreiber, S. L.; Chen, J.; Hung, D. T. Chem. Biol. 1996, 3, 287; (c) Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1997, 52, 613; (d) Balachandran, R.; ter Haar, E.; Welsh, M. J.; Grant, S. G.; Day, B. W. Anti-Cancer Drugs 1998, 9, 67; (e) Martello, M. A.; McDaid, H. M.; Regl, D. L.; Yang, C. H.; Meng, D.; Pettus, T. R. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., III; Horwitz, S. B. Clin. Cancer Res. 2000, 6, 1978; (f) Kar, S.; Florence, G. J.; Paterson, I.; Amos, L. A. FEBS Letters 2003, 539, 34.
8. For biological studies, see: (a) ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243; (b) Schreiber, S. L.; Chen, J.; Hung, D. T. Chem. Biol. 1996, 3, 287; (c) Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1997, 52, 613; (d) Balachandran, R.; ter Haar, E.; Welsh, M. J.; Grant, S. G.; Day, B. W. Anti-Cancer Drugs 1998, 9, 67; (e) Martello, M. A.; McDaid, H. M.; Regl, D. L.; Yang, C. H.; Meng, D.; Pettus, T. R. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., III; Horwitz, S. B. Clin. Cancer Res. 2000, 6, 1978; (f) Kar, S.; Florence, G. J.; Paterson, I.; Amos, L. A. FEBS Letters 2003, 539, 34.
9. For biological studies, see: (a) ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243; (b) Schreiber, S. L.; Chen, J.; Hung, D. T. Chem. Biol. 1996, 3, 287; (c) Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1997, 52, 613; (d) Balachandran, R.; ter Haar, E.; Welsh, M. J.; Grant, S. G.; Day, B. W. Anti-Cancer Drugs 1998, 9, 67; (e) Martello, M. A.; McDaid, H. M.; Regl, D. L.; Yang, C. H.; Meng, D.; Pettus, T. R. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., III; Horwitz, S. B. Clin. Cancer Res. 2000, 6, 1978; (f) Kar, S.; Florence, G. J.; Paterson, I.; Amos, L. A. FEBS Letters 2003, 539, 34.
10. For biological studies, see: (a) ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243; (b) Schreiber, S. L.; Chen, J.; Hung, D. T. Chem. Biol. 1996, 3, 287; (c) Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R. E.; Day, B. W.; Hamel, E. Mol. Pharmacol. 1997, 52, 613; (d) Balachandran, R.; ter Haar, E.; Welsh, M. J.; Grant, S. G.; Day, B. W. Anti-Cancer Drugs 1998, 9, 67; (e) Martello, M. A.; McDaid, H. M.; Regl, D. L.; Yang, C. H.; Meng, D.; Pettus, T. R. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., III; Horwitz, S. B. Clin. Cancer Res. 2000, 6, 1978; (f) Kar, S.; Florence, G. J.; Paterson, I.; Amos, L. A. FEBS Letters 2003, 539, 34.
11. Kinder, F. R.; Bair, K. W.; Chen, W. C.; Florence, G.; Francavilla, C.; Geng, P.; Gunasekera, S.; Lassota, P. T.; Longley, R. E.; Palermo, M. G.; Paterson, I.; Pomponi, S.; Ramsay, T. M.; Rogers, L.; Sabio, M.; Sereinig, N.; Sorenson, E.; Wang, R. M.; Wright, A.; Guo, Q. Abstracts of Papers, 224th National Meeting of the American Chemical Society, Boston, MA, August 18-22, 2002; 236-MEDI, Part 2; ACS, Washington, DC, 2002.
12. Paterson I., Florence G.J. Tetrahedron Lett. 41:2000;6935.
13. Nerenberg J.B., Hung D.T., Schreiber S.L. J. Am. Chem. Soc. 118:1996;11054.
14. Martello L.A., LaMarche M.J., He L., Beauchamp T.J., Smith A.B., Horwitz S.B. Chem. Biol. 8:2001;843.
15. Gunasekera S.P., Longley R.E., Isbrucker R.A. J. Nat. Prod. 64:2001;171.
16. Gunasekera S.P., Paul G.K., Longley R.E., Isbrucker R.A., Pomponi S.A. J. Nat. Prod. 65:2002;1643.
17. Gunasekera S.P., Longley R.E., Isbrucker R.A. J. Nat. Prod. 65:2002;1830.
18. Shin Y., Choy N., Turner T.R., Balachandran R., Madiraju C., Day B.W., Curran D.P. Org. Lett. 4:2002;4443.
19. Choy N., Shin Y., Nguyen P.Q., Curran D.P., Balachandran R., Madiraju C., Day B.W. J. Med. Chem. 46:2003;2846.
20. Minguez J.M., Kim S.-Y., Giulano K.A., Balachandran R., Madiraju C., Day B.W., Curran D.P. Biorg. Med. Chem. 11:2003;3335.
21. Paterson I., Florence G.J., Gerlach K., Scott J.P. Angew. Chem. Int. Ed. 39:2000;377.
22. Paterson I., Florence G.J., Gerlach K., Scott J.P., Sereinig S. J. Am. Chem. Soc. 123:2001;9535.
23. Paterson I., Delgado O., Florence G.J., Lyothier I., Scott J., Sereinig N. Org. Lett. 5:2003;35.
24. A 20,000 step Monte Carlo search was performed for the structures 1, 3 and 4 using the AMBER force field, together with the generalised Born/surface area (CB/SA) water solvent model. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. J. Comp. Chem. 1990, 11, 440.
25. In each case, we found several discrete families of low energy conformations, as anticipated from the results of Snyder and co-workers. For conformational studies on discodermolide, see: (a) Monteagudo, E.; Cicero, D. O.; Cornett, B.; Myles D. C.; Snyder, J. P. J. Am. Chem. Soc. 2001, 123, 6929; (b) Smith, A. B., III; La Marche, M. J.; Falcone-Hindley, M. Org. Lett. 2001, 3, 695.
26. In each case, we found several discrete families of low energy conformations, as anticipated from the results of Snyder and co-workers. For conformational studies on discodermolide, see: (a) Monteagudo, E.; Cicero, D. O.; Cornett, B.; Myles D. C.; Snyder, J. P. J. Am. Chem. Soc. 2001, 123, 6929; (b) Smith, A. B., III; La Marche, M. J.; Falcone-Hindley, M. Org. Lett. 2001, 3, 695.
27. De Mico A., Margarita R., Parlanti L., Vescovi A., Piancatelli G. J. Org. Chem. 62:1997;6974.
28. Still W.C., Gennari C. Tetrahedron Lett. 24:1983;4405.
29. Kocovsky P. Tetrahedron Lett. 27:1986;5521.
30. Paterson I., Goodman J.M., Lister M.A., Schumann R.C., McClure C.K., Norcross R.D. Tetrahedron. 46:1990;4663.
31. Paterson I., Oballa R.M., Norcross R.D. Tetrahedron Lett. 37:1996;8581.
32. Evans D.A., Chapman K.T., Carreira E.M. J. Am. Chem. Soc. 110:1988;3560.
33. + 614.3669, found 614.3671.
34. On acid treatment of 19, rapid deprotection of the two TBS groups and the TES group was accomplished in 80% yield in 1 h. In contrast, the TBS ether at C3 on the δ-lactone of discodermolide requires prolonged treatment with acid (2-3 days) for complete removal and this was found to be incompatible with the oxetane group.
35. + 615.3509, found 615.3516.